Literature DB >> 9057426

Escherichia coli O157:H7--two case reports.

J M Lee1, B Crowley, P A Cahill, D S O'Briain, C Keane, D G Gill, C A O'Morain.   

Abstract

Since the early 1980s the reports of infection and illness associated with Escherichia coli O157:H7 have increased dramatically worldwide, and particularly in the USA, Canada and UK. The spectrum of disease varies from asymptomatic carriage to haemorrhagic colitis and haemolytic uraemic syndrome (HUS). This infection is new to Ireland, and we report on 2 cases of isolation which outline the presentation of this organism with haemorrhagic colitis and HUS.

Entities:  

Mesh:

Year:  1997        PMID: 9057426     DOI: 10.1007/bf02939770

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  5 in total

Review 1.  The epidemiology of infections caused by Escherichia coli O157:H7, other enterohemorrhagic E. coli, and the associated hemolytic uremic syndrome.

Authors:  P M Griffin; R V Tauxe
Journal:  Epidemiol Rev       Date:  1991       Impact factor: 6.222

Review 2.  Escherichia coli O157:H7 and the hemolytic-uremic syndrome.

Authors:  T G Boyce; D L Swerdlow; P M Griffin
Journal:  N Engl J Med       Date:  1995-08-10       Impact factor: 91.245

3.  Escherichia coli O157:H7-associated colitis. A clinical and histological study of 11 cases.

Authors:  P M Griffin; L C Olmstead; R E Petras
Journal:  Gastroenterology       Date:  1990-07       Impact factor: 22.682

4.  Hemorrhagic colitis associated with a rare Escherichia coli serotype.

Authors:  L W Riley; R S Remis; S D Helgerson; H B McGee; J G Wells; B R Davis; R J Hebert; E S Olcott; L M Johnson; N T Hargrett; P A Blake; M L Cohen
Journal:  N Engl J Med       Date:  1983-03-24       Impact factor: 91.245

5.  The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli.

Authors:  M A Karmali; M Petric; C Lim; P C Fleming; G S Arbus; H Lior
Journal:  J Infect Dis       Date:  1985-05       Impact factor: 5.226

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.